Entresto

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

sacubitril, valsartan

Available from:

Novartis Europharm Limited

ATC code:

C09DX04

INN (International Name):

sacubitril, valsartan

Therapeutic group:

Angiotensin II antagonisti, druge kombinacije, Agente, ki delujejo na renin-angiotensin sistem

Therapeutic area:

Odpoved srca

Therapeutic indications:

Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Product summary:

Revision: 18

Authorization status:

Pooblaščeni

Authorization date:

2015-11-19

Patient Information leaflet

                                53
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/15/1058/001
28 filmsko obloženih tablet
EU/1/15/1058/008
14 filmsko obloženih tablet
EU/1/15/1058/009
20 filmsko obloženih tablet
EU/1/15/1058/010
56 filmsko obloženih tablet
EU/1/15/1058/018
196 filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Entresto 24 mg/26 mg filmsko obložene tablete, skrajšana oblika je
sprejemljiva, če je potrebna iz
tehničnih razlogov
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
54
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z "BLUE BOX" PODATKI)
1.
IME ZDRAVILA
Entresto 24 mg/26 mg filmsko obložene tablete
sakubitril/valsartan
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena 24 mg/26 mg tableta vsebuje 24,3 mg sakubitrila in 25,7 mg
valsartana (v obliki kompleksa
natrijeve soli sakubitrila in valsartana).
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
Skupno pakiranje: 196 (7 pakiranj po 28) filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
55
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZD
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Entresto 24 mg/26 mg filmsko obložene tablete
Entresto 49 mg/51 mg filmsko obložene tablete
Entresto 97 mg/103 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Entresto 24 mg/26 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 24,3 mg sakubitrila in 25,7 mg
valsartana (v obliki kompleksa
natrijeve soli sakubitrila in valsartana).
Entresto 49 mg/51 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 48,6 mg sakubitrila in 51,4 mg
valsartana (v obliki kompleksa
natrijeve soli sakubitrila in valsartana).
Entresto 97 mg/103 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 97,2 mg sakubitrila in 102,8 mg
valsartana (v obliki kompleksa
natrijeve soli sakubitrila in valsartana).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Entresto 24 mg/26 mg filmsko obložene tablete
Vijoličasto bela ovalna bikonveksna filmsko obložena tableta z
zaobljenimi robovi, brez razdelilne
zareze in z vtisnjenima oznakama "NVR" na eni strani in "LZ" na drugi.
Tablete so velike približno
13,1 mm x 5,2 mm.
Entresto 49 mg/51 mg filmsko obložene tablete
Bledo rumena ovalna bikonveksna filmsko obložena tableta z
zaobljenimi robovi, brez razdelilne
zareze in z vtisnjenima oznakama "NVR" na eni strani in "L1" na drugi.
Tablete so velike približno
13,1 mm x 5,2 mm.
Entresto 97 mg/103 mg filmsko obložene tablete
Svetlo rožnata ovalna bikonveksna filmsko obložena tableta z
zaobljenimi robovi, brez razdelilne
zareze in z vtisnjenima oznakama "NVR" na eni strani in "L11" na
drugi. Tablete so velike približno
15,1 mm x 6,0 mm.
3
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Srčno popuščanje pri odraslih
Zdravilo Entresto je indicirano za zdravljenje simptomatskega
kroničnega srčnega popuščanja z
zmanjšanim iztisnim deležem pri odraslih bolnikih (glejte poglavje
5.1).
Srčno popuščanje pri pediatričnih bolnikih
Zdravilo Entresto 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 08-12-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 08-12-2023
Public Assessment Report Public Assessment Report Bulgarian 22-06-2023
Patient Information leaflet Patient Information leaflet Spanish 08-12-2023
Public Assessment Report Public Assessment Report Spanish 22-06-2023
Patient Information leaflet Patient Information leaflet Czech 08-12-2023
Public Assessment Report Public Assessment Report Czech 22-06-2023
Patient Information leaflet Patient Information leaflet Danish 08-12-2023
Public Assessment Report Public Assessment Report Danish 22-06-2023
Patient Information leaflet Patient Information leaflet German 08-12-2023
Public Assessment Report Public Assessment Report German 22-06-2023
Patient Information leaflet Patient Information leaflet Estonian 08-12-2023
Public Assessment Report Public Assessment Report Estonian 22-06-2023
Patient Information leaflet Patient Information leaflet Greek 08-12-2023
Public Assessment Report Public Assessment Report Greek 22-06-2023
Patient Information leaflet Patient Information leaflet English 08-12-2023
Public Assessment Report Public Assessment Report English 22-06-2023
Patient Information leaflet Patient Information leaflet French 08-12-2023
Public Assessment Report Public Assessment Report French 22-06-2023
Patient Information leaflet Patient Information leaflet Italian 08-12-2023
Public Assessment Report Public Assessment Report Italian 22-06-2023
Patient Information leaflet Patient Information leaflet Latvian 08-12-2023
Public Assessment Report Public Assessment Report Latvian 22-06-2023
Patient Information leaflet Patient Information leaflet Lithuanian 08-12-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-12-2023
Public Assessment Report Public Assessment Report Lithuanian 22-06-2023
Patient Information leaflet Patient Information leaflet Hungarian 08-12-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 08-12-2023
Public Assessment Report Public Assessment Report Hungarian 22-06-2023
Patient Information leaflet Patient Information leaflet Maltese 08-12-2023
Public Assessment Report Public Assessment Report Maltese 22-06-2023
Patient Information leaflet Patient Information leaflet Dutch 08-12-2023
Public Assessment Report Public Assessment Report Dutch 22-06-2023
Patient Information leaflet Patient Information leaflet Polish 08-12-2023
Public Assessment Report Public Assessment Report Polish 22-06-2023
Patient Information leaflet Patient Information leaflet Portuguese 08-12-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 08-12-2023
Public Assessment Report Public Assessment Report Portuguese 22-06-2023
Patient Information leaflet Patient Information leaflet Romanian 08-12-2023
Public Assessment Report Public Assessment Report Romanian 22-06-2023
Patient Information leaflet Patient Information leaflet Slovak 08-12-2023
Public Assessment Report Public Assessment Report Slovak 22-06-2023
Patient Information leaflet Patient Information leaflet Finnish 08-12-2023
Public Assessment Report Public Assessment Report Finnish 22-06-2023
Patient Information leaflet Patient Information leaflet Swedish 08-12-2023
Public Assessment Report Public Assessment Report Swedish 22-06-2023
Patient Information leaflet Patient Information leaflet Norwegian 08-12-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 08-12-2023
Patient Information leaflet Patient Information leaflet Icelandic 08-12-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 08-12-2023
Patient Information leaflet Patient Information leaflet Croatian 08-12-2023
Public Assessment Report Public Assessment Report Croatian 22-06-2023

Search alerts related to this product

View documents history